Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 187 publications

Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma: Data from the Hungarian Pediatric Oncology Network.

Dinutuximab Beta for the Treatment of High-Risk Neuroblastoma: Data from the Hungarian Pediatric Oncology Network.

Journal: Journal of clinical medicine
Published: August 05, 2025

Ganglioside Profiling Uncovers Distinct Patterns in High-Risk Neuroblastoma.

Ganglioside Profiling Uncovers Distinct Patterns in High-Risk Neuroblastoma.

Journal: International journal of molecular sciences
Published: August 01, 2025

ImmunoPET Demonstrates that Co-Targeting GD2 and B7-H3 with Bispecific Antibodies Enhances Tumor Selectivity in Preclinical Melanoma Models.

ImmunoPET Demonstrates that Co-Targeting GD2 and B7-H3 with Bispecific Antibodies Enhances Tumor Selectivity in Preclinical Melanoma Models.

Journal: Bioconjugate chemistry
Published: July 31, 2025

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Journal: Cancers
Published: July 24, 2025

Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 23, 2025

Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition.

Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition.

Journal: Cancers
Published: June 04, 2025

Chemo-Immunotherapy Rescue for High-Risk Neuroblastoma Patients With Progressive Disease Before High-Dose Chemotherapy: Real-World Data From the SACHA-France Study.

Chemo-Immunotherapy Rescue for High-Risk Neuroblastoma Patients With Progressive Disease Before High-Dose Chemotherapy: Real-World Data From the SACHA-France Study.

Journal: Pediatric blood & cancer
Published: May 28, 2025

Automated zirconium-89 and lutetium-177 antibody labeling and formulation using a Trasis MiniAIO module.

Automated zirconium-89 and lutetium-177 antibody labeling and formulation using a Trasis MiniAIO module.

Journal: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
Published: May 19, 2025

Efficacy and Safety of Anti-GD2 Immunotherapy with Dinutuximab Beta in the Treatment of Relapsed/Refractory High-Risk Neuroblastoma.

Efficacy and Safety of Anti-GD2 Immunotherapy with Dinutuximab Beta in the Treatment of Relapsed/Refractory High-Risk Neuroblastoma.

Journal: Targeted oncology
Published: May 13, 2025

Ocular Toxicity in GD-2 Antibody Therapy: A Case Study.

Ocular Toxicity in GD-2 Antibody Therapy: A Case Study.

Journal: Journal of pediatric hematology/oncology nursing
Published: April 18, 2025

Therapeutic Innovation in Pediatric Neuroblastoma: Age and Stage-Specific Strategies from Prenatal to Early Childhood-A Review Article.

Therapeutic Innovation in Pediatric Neuroblastoma: Age and Stage-Specific Strategies from Prenatal to Early Childhood-A Review Article.

Journal: Iranian journal of child neurology
Published: April 12, 2025

Single-Center Cohort of Pediatric Patients with High-Risk Neuroblastoma Receiving Immunotherapy.

Single-Center Cohort of Pediatric Patients with High-Risk Neuroblastoma Receiving Immunotherapy.

Journal: Cancers
Published: April 02, 2025
Showing 1-12 of 187

Last Updated: 10/31/2025